Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany

Background and Objectives Over the last decade, significant advancements have been made in status epilepticus (SE) management, influenced by landmark trials such as ESETT and RAMPART. The objectives of this study were to explore the evolution of drug treatments for patients with SE, to investigate i...
Ausführliche Beschreibung

Background and Objectives Over the last decade, significant advancements have been made in status epilepticus (SE) management, influenced by landmark trials such as ESETT and RAMPART. The objectives of this study were to explore the evolution of drug treatments for patients with SE, to investigate its association with outcomes and mortality, and to evaluate differences in treatment patterns between adults and children for a potential shift in medication trends due to the above mentioned trials. Methods The medical records of patients with SE treated at University Hospital Frankfurt between 2012 and 2021 were evaluated for medication trends and outcomes. Children and adults were analyzed separately and jointly. Results This study included 1151 SE episodes in 1021 patients (mean age = 53.3 ± 28.3 years; 52.5 % female [n = 533]). The overall percentage of patients with SE treated prehospital was stable over the last decade. More than half (53.6 %) of children were treated prehospital, compared with less than one-third (26.7 %) of adults. Prehospital midazolam use increased over time, while diazepam use decreased. Lorazepam was the most commonly used benzodiazepine in hospitals in 2012–2013, used in 40.8 % of all episodes. However, its use declined to 27.2 % in 2020–2021, while midazolam use increased to 44.0 %. While the use of older antiseizure medications (ASMs) such as phenobarbital (p = 0.02), phenytoin (p < 0.001), and valproate (p < 0.001) decreased, the use of newer ASMs such as levetiracetam and lacosamide significantly increased (p < 0.001). Propofol and continuous midazolam infusion remained the most used third-line therapy drugs. Overall mortality was 16.5 % at discharge and 18.9 % at 30 days. Mortality rates did not change between 2012 and 2021. Conclusion Midazolam has become the preferred benzodiazepine in pre- and in-hospital settings, both in children and adults. The same applies to the increased use of levetiracetam and lacosamide over time in children and adults, while phenobarbital, phenytoin, and valproate use decreased. Continuous midazolam infusion and propofol remain the most frequently used anesthetic drugs. Mortality and outcome remain stable despite changes in medication patterns. Ausführliche Beschreibung

Autor*in:	Purwien, Leonore [verfasserIn] Schubert-Bast, Susanne Kieslich, Matthias Ronellenfitsch, Michael W. Merker, Michael Czabanka, Marcus Willems, Laurent M. Rosenow, Felix Strzelczyk, Adam

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Anmerkung:	© The Author(s) 2023

Übergeordnetes Werk:	Enthalten in: CNS drugs - Berlin [u.a.] : Springer, 1994, 37(2023), 11 vom: Nov., Seite 993-1008
Übergeordnetes Werk:	volume:37 ; year:2023 ; number:11 ; month:11 ; pages:993-1008

Links:	Volltext

DOI / URN:	10.1007/s40263-023-01049-w

Katalog-ID:	SPR053842715